Merck & Company, Inc. (NYSE:MRK) is one of the high-margin pharma stocks to buy now. Jefferies has raised its price target on ...

President Trump is readying plans for industry-specific tariffs to kick in alongside his country-by-country duties in two ...

The company had previously halted shipments to certain older patients following the deaths of two teenagers treated with the ...

Johnson & JohnsonJNJ, on its second-quarter conference call, stated that it expects its oncology sales to reach $50 billion ...

ZoomRx surveyed 57 neurologists in the U.S. this month, revealing that no single drug brand holds more than 5% of top-of-mind ...

Market OverviewThe global Cancer Immunotherapy Market is valued at USD 121.4 Billion in 2024 and is projected to reach a ...

Merck & Co. faces headwinds despite being labeled an undervalued stock. Morgan Stanley recently lowered its price target to ...

Overall venture funding, as well as “first financing” rounds, fell significantly in the second quarter, reversing 2025’s fast ...

Yale SOM leadership expert Jeffrey Sonnenfeld and co-author Steven Tian argue that Cook’s unmatched track record makes him uniquely positioned to steer the company into its next phase of innovation ...

LLY's explosive growth from Mounjaro and Zepbound outpaces MRK's Keytruda-led gains, despite valuation concerns.

Merck aims to boost its business by buying Verona Pharma for $10 billion. Through the deal, it will add Ohtuvayre -- a ...

Merck is making big pharma waves again with a $10 billion deal to acquire Verona Pharma, reports Colin Kellaher for the Wall ...